Study Details

Back to Search Results

A Randomized Study of Enzalutamide in Patients with Localized Prostate Cancer Undergoing Active Surveillance

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02799745

Astellas Study ID

The unique identification code given by the study sponsor.

9785-MA-1010

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Prostate Cancer

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 years - N/A

Sex

Male

Product

enzalutamide

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jun 2016 - Aug 2020

Masking

None (Open Label)

Enrollment number

227

A Randomized Study of Enzalutamide in Patients with Localized Prostate Cancer Undergoing Active Surveillance (ENACT)

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Randomized Study of Enzalutamide in Patients with Localized Prostate Cancer Undergoing Active Surveillance? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site US10044

Omaha, United States, 68114

Site US10021

Syracuse, United States, 13210

Site US10050

Cheektowaga, United States, 14225

Site US10037

New Orleans, United States, 70112

Site US10019

Myrtle Beach, United States, 29572

Site US10040

Melrose Park, United States, 60160

Site US10015

Middleburg Heights, United States, 44130

Site US10043

Voorhees, United States, 08043

Site CA15003

Toronto, Canada, M5G2M9

Site US10056

Dallas, United States, 75231

Site US10036

Houston, United States, 77027

Site US10070

Chicago, United States, 60643

Site US10041

Burien, United States, 98166

Site US10063

Bala Cynwyd, United States, 19004

Site US10029

Denver, United States, 80211

Site US10022

Syracuse, United States, 13210

Site US10055

Tucson, United States, 85741

Site US10072

Bradenton, United States, 34205

Site CA15001

Toronto, Canada, M4N3M5

Site US10069

Lincoln, United States, 68516

Site US10052

Lancaster, United States, 17604

Site US10061

Lebanon, United States, 03756

Site US10002

San Diego, United States, 92120

Site US10001

Towson, United States, 21204

Site US10048

Chicago, United States, 60637

Site US10038

Chicago, United States, 60611

Site US10064

San Jose, United States, 95124

Site US10007

Tucson, United States, 85704

Site CA15005

Abbotsford, Canada, V2S 3N6

Site US10066

Atlanta, United States, 30312

Site US10071

Lake Barrington, United States, 60010

Site US10017

Milwaukee, United States, 53226

Site US10045

Cleveland, United States, 44195

Site US10058

Richmond, United States, 23235

Site US10025

Hanover, United States, 21076

Site US10030

Garden City, United States, 11530

Site US10067

Omaha, United States, 68130

Site US10049

Morristown, United States, 07962

Site US10054

Denver, United States, 80220

Site US10023

Seattle, United States, 98101

Site US10009

Jeffersonville, United States, 47130

Site US10020

Winston Salem, United States, 27157

Site US10024

Homewood, United States, 35209

Site US10074

Chicago, United States, 60612

Site US10047

Gastonia, United States, 28053

Site US10035

San Antonio, United States, 78229

Site US10034

Birmingham, United States, 35223

Site US10039

Englewood, United States, 07631

Site US10028

Poughkeepsie, United States, 12601

Site US10051

Aurora, United States, 80045

Site US10062

Chicago, United States, 60612

Site US10018

Glenview, United States, 60026

Site US10014

Warwick, United States, 02886

Site US10068

Brooklyn, United States, 11215

Site US10004

Los Angeles, United States, 90048

Site US10008

Troy, United States, 48084

Site US10010

San Diego, United States, 92123

Site US10032

Boston, United States, 02111

Site US10053

Oklahoma City, United States, 73104

Site US10026

Sacramento, United States, 95670

Site US10046

Carmel, United States, 46033

Site US10057

Lakeland, United States, 33805

Site US10006

Shreveport, United States, 71106

Site CA15004

Halifax, Canada, B3H 2Y9

Site US10011

Nashville, United States, 37209

Site US10005

Anchorage, United States, 99503

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo